The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Jean-Yves Blay

Department of Medical Oncology

Centre Léon Bérard

France

[email]@*.fnclcc.fr

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Medical Oncology, Centre Léon Bérard, France. 1997 - 2011
  • Léon Bérard Comprehensive Cancer Centre, Université Claude Bernard Lyon I, France. 2010
  • Leon Berard Center, Claude Bernard University, France. 2010
  • Cytokine and Cancer Unit, Léon Bérard Cancer Centre, 28 rue Laennec, 69008 Lyon, France. 2009
  • CONTICANET and UJOMM Hôpital Edouard Herrot, Centre Léon Bérard, France. 2008
  • Unité INSERM 590, Centre Léon Bérard, 69008 Lyon and Hopital Edouard Herriot, Place d'Arsonval, France. 2005 - 2007
  • Hôpital Edouard-Herriot, Oncologie médicale, Pavillon E, 5 place d'Arsonval, France. 2007
  • Hospices Civils de Lyon & Ctr L.Bérard, France. 2003
  • Centre Léon Bérard, France. 1998 - 2000
  • Centre Léon Bérard and Hôpital Edouard Herriot, France. 2000
  • EORTC Soft Tissue and Bone Sarcoma Group, Brussels, Belgium. 1999
  • PARMA Cooperative Group (with Fédération Nationale des Centres de Lutte Contre le Cancer [FNCLCC], Dutch Haemato-Oncology Working Party [HOVON], European Organization for Research and Treatment of Cancer [EORTC], France. 1998

References

  1. Updating progress in sarcoma therapy with mTOR inhibitors. Blay, J.Y. Ann. Oncol. (2011) [Pubmed]
  2. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Blay, J.Y. Ann. Oncol. (2010) [Pubmed]
  3. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Blay, J.Y., von Mehren, M., Blackstein, M.E. Cancer (2010) [Pubmed]
  4. Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour? Blay, J.Y., Adenis, A., Ray-Coquard, I., Cassier, P.A., Le Cesne, A. Curr. Opin. Oncol (2009) [Pubmed]
  5. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. Blay, J.Y., Reichardt, P. Expert. Rev. Anticancer. Ther (2009) [Pubmed]
  6. New paradigms in gastrointestinal stromal tumour management. Blay, J.Y. Ann. Oncol. (2009) [Pubmed]
  7. Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven. Blay, J.Y., Le Cesne, A. Oncologist (2009) [Pubmed]
  8. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Blay, J.Y., von Mehren, M., Samuels, B.L., Fanucchi, M.P., Ray-Coquard, I., Buckley, B., Gilles, L., Lebedinsky, C., Elsayed, Y.A., Le Cesne, A. Clin. Cancer Res. (2008) [Pubmed]
  9. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. Blay, J.Y., Le Cesne, A., Ray-Coquard, I., Bui, B., Duffaud, F., Delbaldo, C., Adenis, A., Viens, P., Rios, M., Bompas, E., Cupissol, D., Guillemet, C., Kerbrat, P., Fayette, J., Chabaud, S., Berthaud, P., Perol, D. J. Clin. Oncol. (2007) [Pubmed]
  10. Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE). Blay, J.Y., Koscielny, S., Trédaniel, J., Asselain, B., Goldwasser, F., Misset, J.L., de Labareyre, C., Hagège, C., Bismut, H., Marty, M. Crit. Rev. Oncol. Hematol. (2007) [Pubmed]
  11. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Blay, J.Y., Bonvalot, S., Casali, P., Choi, H., Debiec-Richter, M., Dei Tos, A.P., Emile, J.F., Gronchi, A., Hogendoorn, P.C., Joensuu, H., Le Cesne, A., McClure, J., Mac Clure, J., Maurel, J., Nupponen, N., Ray-Coquard, I., Reichardt, P., Sciot, R., Stroobants, S., van Glabbeke, M., van Oosterom, A., Demetri, G.D. Ann. Oncol. (2005) [Pubmed]
  12. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Blay, J.Y., van Glabbeke, M., Verweij, J., van Oosterom, A.T., Le Cesne, A., Oosterhuis, J.W., Judson, I., Nielsen, O.S. Eur. J. Cancer (2003) [Pubmed]
  13. Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Fédération Nationale des Centres de Lutte contre le Cancer. Blay, J.Y., Ongolo-Zogo, P., Sebban, C., Carrie, C., Thiesse, P., Biron, P. Ann. Oncol. (2000) [Pubmed]
  14. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. Blay, J.Y., Bouhour, D., Ray-Coquard, I., Dumontet, C., Philip, T., Biron, P. J. Clin. Oncol. (2000) [Pubmed]
  15. Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Blay, J.Y., Judson, I., Rodenhuis, S., Hermans, C., Smith, M., van Glabbeke, M., Verweij, J. Anticancer. Drugs (1999) [Pubmed]
  16. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. Blay, J.Y., Conroy, T., Chevreau, C., Thyss, A., Quesnel, N., Eghbali, H., Bouabdallah, R., Coiffier, B., Wagner, J.P., Le Mevel, A., Dramais-Marcel, D., Baumelou, E., Chauvin, F., Biron, P. J. Clin. Oncol. (1998) [Pubmed]
  17. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blay, J.Y., Le Cesne, A., Mermet, C., Maugard, C., Ravaud, A., Chevreau, C., Sebban, C., Guastalla, J., Biron, P., Ray-Coquard, I. Blood (1998) [Pubmed]
  18. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blay, J., Gomez, F., Sebban, C., Bachelot, T., Biron, P., Guglielmi, C., Hagenbeek, A., Somers, R., Chauvin, F., Philip, T. Blood (1998) [Pubmed]
  19. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Blay, J.Y., Rossi, J.F., Wijdenes, J., Menetrier-Caux, C., Schemann, S., Négrier, S., Philip, T., Favrot, M. Int. J. Cancer (1997) [Pubmed]
 
WikiGenes - Universities